Oncology Advances in Focus: Dr. Rainer Lipp’s Research on NSCLC

 We are pleased to share that Dr. Rainer Lipp, Co-founder of GermanOncology GmbH, Germany, will present his latest research at the International Conference on Cancer Science and Research, happening November 17–19, 2025, in Singapore & Online.

🩺 Presentation Title

General and age-dependent development of firstline (1L) therapies in patients with metastatic non-small cell lung cancer (NSCLC) from 2016–2024 in the standard care situation of oncological practices

📌 Key Highlights from the Study

• Data analyzed from 1,250 patients treated in 25 oncological practices across Germany (2016–2024).
• Median patient age: 68 years; with 76.8% ≤75 years and 23.2% >75 years.
• Over the last 8 years, a shift from chemotherapy to immunotherapy combinations was observed.
• ICI (Immune Checkpoint Inhibitor) use grew from 33.1% (2016–2019) to 79.9% (2022–2024).
• Traditional chemotherapy ± Bevacizumab declined from 58.4% to 13.6%.
• Patients >75 years were more frequently treated with ICI monotherapy (30.3%), while younger patients ≤75 years saw higher use of ICI combinations (59.6%).
• Findings highlight the age-dependent treatment trends shaping NSCLC standard care.

👨‍⚕️ About the Speaker

Dr. Rainer Lipp is a board-certified hematologist and medical oncologist, specializing in real-world standard care research in hematology and oncology. He has held positions at the Lung Clinic Großhansdorf, University Hospital Münster, and University Hospital Hamburg-Eppendorf.

As Co-founder of GermanOncology GmbH, he leads a network of 20+ oncology practices, building a database of 15,000+ longitudinal patient datasets. Dr. Lipp also manages non-interventional studies for pharmaceutical companies and supports healthcare consulting in hospital outpatient settings and reimbursement processes.

📅 Event Information

Event Name: International Conference on Cancer Science and Research
Dates: November 17–19, 2025
Venue: Village Hotel Changi, Singapore & Online

🌐 Event Website
📝 Register Here
✍️ Submit Abstract

📧 cancer@mathewsconference.com | 📞 +1 (312) 462-4448 | WhatsApp: +1 (424) 377 0967
Follow us on X for live updates.

---

#CancerScience2025 #OncologyResearch #LungCancer #NSCLC #Immunotherapy #CancerConference #MedicalOncology #CancerTreatment #CancerCare #OncologyUpdates

Advancing Cancer Science with Nanocomposites and RF Applications

 We are delighted to announce that Prof. Paulo César De Morais, Catholic University of Brasília, Brazil, will deliver a keynote talk at the International Conference on Cancer Science and Research, scheduled for November 17–19, 2025, in Singapore.

His keynote presentation, titled:
“Cell viability assays under radiofrequency application modulated by nanomaterials”
will explore cutting-edge research at the intersection of nanotechnology, oncology, and radiofrequency-based therapy.

🔬 Key Highlights of the Presentation:

·         Application of the Hill model to analyze BMD (Benchmark Dose), LD50 (Lethal Dose 50), cooperativity (E), and dissociation constant (K).

·         Insights into the synergistic effects of nanomaterials and radiofrequency (RF) in cancer treatment.

·         Discussion on nanocomposites such as Graphene Oxide (GO) functionalized with polyethyleneimine (PEI) and decorated with gold nanoparticles (GO-PEI-Au).

·         Findings from cell viability assays using tumor cell lines like LLC-WRC-256 and B16-F10.

·         Evidence that while nanocomposites remain biocompatible without RF, the application of RF enhances cancer cell toxicity by several orders of magnitude.

·         Future outlook on applying these results to tumor animal models for advanced cancer research.

👨‍🏫 About the Speaker:

Prof. Paulo César De Morais, PhD, is an Emeritus Professor of Physics at the University of Brasília and a CNPq-1A Research Fellow. With more than 13,500 citations, 500+ publications, and 16 patents, he is a leading figure in nanotechnology and cancer science. He has presented over 200 invited talks across 35 countries, making him a globally recognized expert in his field.

---

📅 Event Dates: November 17–19, 2025
📍 Venue: Village Hotel Changi, 1 Netheravon Rd, Singapore 508502
🔗 Website: https://cancer.miconferences.com/
✍️ Register Here: Click to Register
📩 Submit Abstract: Click to Submit

📞 Contact Us:
Email: cancer@mathewsconference.com | Phone: +1 (312) 462-4448 | WhatsApp: +1 (424) 377 0967

🌍 Follow Us:

·         Facebook

·         X (Twitter)

---

#CancerConference2025 #CancerResearch #CancerScience #Nanomaterials #RadiofrequencyTherapy #OncologyResearch #CancerWorldConf #MathewsConferences #SingaporeConference #CancerInnovation

Advancing Cancer Care: Stem Cell Therapy for Radiotherapy Complications

Featured Speaker: Dr. Alain Chapel, Institute of Radiological Protection and Nuclear Safety, France

Session Type: Oral Virtual Presentation

Topic: From experimental research to clinical trial in the treatment of complication of radiotherapy by stem cells

---

🌟 Why This Research Matters

Radiotherapy remains a cornerstone in cancer treatment, but nearly 5–10% of patients develop serious long-term side effects, especially after pelvic radiation. These complications often lack standardized treatment, making innovation in this area a pressing need. Dr. Alain Chapel and his team have been exploring mesenchymal stromal stem cell (MSC) therapy as a potential breakthrough solution.

---

🔍 Key Insights from the Study

·         Clinical Problem: Late adverse gastrointestinal and pelvic complications post-radiotherapy can be life-threatening.

·         Preclinical Evidence: Animal models demonstrated that systemic MSC injections significantly alleviated radiation-induced damage.

·         Phase I Clinical Trial Results:

o    Patients experienced reduction in diarrhea, pain, hemorrhage, and inflammation.

o    Fistulization process was halted in one patient with remission lasting over 3 years.

o    No toxicity observed, supporting a favorable safety profile.

·         Ongoing PRISME Trial (NCT02814864):

o    Involves 12 patients across 6 radiotherapy centers.

o    Each patient receives three MSC injections at weekly intervals.

o    Primary goal: measurable improvement on LENT SOMA scale for rectal bleeding or hematuria.

o    Secondary goals: reduced need for pain medication, fewer digestive issues, and better quality of life.

·         Future Outlook: A Phase III clinical trial is planned if current results confirm long-term efficacy.

---

👨‍🔬 About Dr. Alain Chapel

Dr. Alain Chapel, PhD, has dedicated more than 30 years to advancing cell and gene therapy for radiation-induced damage. His work bridges experimental models with real-world clinical applications. He has collaborated on groundbreaking compassionate trials demonstrating MSC therapy’s effectiveness in hematopoietic failure, radiodermatitis, and radiotherapy overdoses. His extensive contributions also include editorial roles in leading international journals and active participation in global research societies.

---

📢 Join the Conference

Be part of this global platform where cutting-edge cancer research meets clinical innovation.

Event: International Conference on Cancer Science and Research

📍 Venue: Village Hotel Changi, Singapore
📅 Dates: November 17–19, 2025
🌐 Website: cancer.miconferences.com
✉️ Email: cancer@mathewsconference.com
📞 Phone: +1 (312) 462-4448 | WhatsApp: +1 (424) 377 0967

👉 Register Now | Submit Abstract

---

#CancerScience2025 #StemCellResearch #RadiotherapyComplications #CancerTreatment #OncologyConference #MSCtherapy #CancerInnovation #CancerResearch

Endothelial RhoA: Unlocking a New Frontier in Anti-Metastatic Cancer Therapy

 📅 Event Dates: November 17–19, 2025

📍 Venue: Village Hotel Changi, Singapore | 🌐 Hybrid (In-Person & Virtual)
🎤 Speaker: Dr. Constantinos M. Mikelis, University of Patras, Greece

Title : The regulatory role of endothelial RhoA on tumor microenvironment

---

🔬 Presentation Highlights

·        The endothelial barrier actively regulates tumor growth, dissemination, and metastasis.

·         Transendothelial migration of tumor cells is a key step in metastasis.

·         Research findings show that endothelial RhoA activation plays a decisive role in this process.

·         Breast tumor cells trigger endothelial RhoA via paracrine signaling and cell-to-cell contact.

·         Blocking RhoA genetically or pharmacologically reduces tumor cell migration and metastasis in human and murine tumor models.

·         These results identify endothelial RhoA as a universal therapeutic target for anti-metastatic treatment of solid tumors.

👨‍🔬 About Dr. Constantinos M. Mikelis

·         Associate Professor of Physiology at the University of Patras, Greece.

·         Adjunct Associate Professor at Texas Tech University Health Sciences Center, USA.

·         PhD focused on angiogenesis, University of Patras.

·         Postdoctoral training at NIH, USA in vascular and cancer biology.

·         Research expertise: Small GTPases, GPCRs, angiogenesis, endothelial biology, and tumor microenvironment.

📢 About the Event – International Conference on Cancer Science and Research 2025

This global event will gather leading oncologists, researchers, clinicians, and industry experts to share cutting-edge advancements in cancer biology, therapy, and clinical research.

·         🌍 Hybrid Mode: Attend in Singapore or join virtually.

·         📄 Abstract Submission: Click Here

·         📝 Registration: Click Here

·         🔗 Event Website

📧 Email: cancer@mathewsconference.com
📞 Phone: +1 (312) 462-4448
📲 WhatsApp: +1 (424) 377 0967

🔗 Social: Facebook | X (Twitter)

---

#CancerScience2025 #InternationalCancerConference #CancerResearch #TumorMicroenvironment #EndothelialRhoA #OncologyConference #SingaporeConference

Copper(II) Complexes: A New Horizon in Cancer Chemotherapy

 Featuring Dr. Salah S. Massoud – University of Louisiana, United States

📍 Oral In-Person Presentation at the International Conference on Cancer Science andResearch
📅 November 17–19, 2025 | Village Hotel Changi, Singapore

Title: Copper(II) complexes as potent chemotherapeutic agents for anticancer therapy

---

Why Copper(II) Complexes?

Cancer continues to be one of the most critical health challenges of our time. According to the World Health Organization (WHO), cancer claimed nearly 10 million lives in 2022, and projections suggest this number may rise to 16.4 million by 2040. While platinum-based drugs such as cisplatin, carboplatin, and oxaliplatin revolutionized chemotherapy, their severe side effects—including nephrotoxicity, neurotoxicity, immune suppression, and drug resistance—have limited their long-term effectiveness.

In this context, Copper(II) complexes are emerging as powerful candidates for next-generation chemotherapy. Over the past two decades, research has revealed their high cytotoxicity, better pharmacological profiles, and selective action against cancer cells. Notably, binuclear pyridyl-phenoxido Cu(II) complexes demonstrated remarkable antiproliferative activity with a high selectivity index in ovarian (A2780) and breast cancer (MCF-7) cell lines. Dr. Massoud’s presentation will highlight how these complexes function, their mechanisms of action, and their potential to transform cancer therapy.

---

About the Speaker

Dr. Salah S. Massoud is a renowned Distinguished Professor at the University of Louisiana, USA, and Alexandria University, Egypt. He earned his Ph.D. in Bioinorganic and Inorganic Chemistry from Boston University, following his B.Sc. and M.Sc. from Alexandria University.

His scientific journey is remarkable—200+ peer-reviewed publications, 200+ invited lectures worldwide, and groundbreaking research contributions in copper-based anticancer drugs, DNA cleavage, ATP hydrolysis, molecular magnetism, and lanthanide fluorescence. Beyond his research, Dr. Massoud actively serves on editorial boards and as a guest editor for leading scientific journals, influencing the global scientific community.

---

Conference Information

Event: International Conference on Cancer Science and Research

📅 Dates: November 17–19, 2025

📍 Venue: Village Hotel Changi, 1 Netheravon Rd, Singapore 508502

📧 Email: cancer@mathewsconference.com
📞 Phone: +1 (312) 462-4448
💬 WhatsApp: +1 (424) 377 0967

🔗 Stay connected: Facebook | X (Twitter)

🔗 Click here to Register | Submit Your Abstract

#CancerResearch #OncologyConference #CancerScience2025 #CopperComplexes #CancerTherapy #ChemotherapyResearch #OncologyInnovation #MedicalResearch

Cardiac Coherence: A New Approach to Oncology Medicine

We are delighted to feature Nabhan Linda, Clinical Psychologist from France Digital University, France, who will be delivering a Poster Virtual Presentation at the International Conference on Cancer Science and Research, scheduled for November 17–19, 2025, at the Village Hotel Changi, Singapore.

---

Abstract

In the oncology clinic, the issue of anguish, stress and anxiety is a very important part of treatment. These affects can also condition the outcome of treatment, as well as patients' experiences of their disease. Cancer has specific psychological repercussions compared with other illnesses that do not call so deeply on the subject's being. How can we deal with anxiety other than by taking medication? From patients who have never used anxiolytics or antidepressants to those who are wary of them, the powerlessness in the face of such intimate and intrinsic suffering is being felt. Indeed, anxiety is at the heart of the patient's history. Not everyone experiences anxiety in the same way, or for the same reasons. On the one hand, it is a question of identifying these types of feelings and then trying to understand the ins and outs of them. There's something quite special about psychological suffering: it can't be understood. In other words, there is an inability to share feelings with others that plunges the subject into this distress. Welcoming people with words is our first line of approach to this suffering, but how can we really act? This is where the relevance of cardiac coherence comes in.

Cardiac coherence is a method of refocusing the subject which has a dual effect on the nervous system by activating breathing, and which in turn has an impact on the psyche.

What was interesting to observe was that, in reality, once in a state of anxiety, the emergency having been declared, it is extremely difficult to act on these moments when the patient is in a state of total feeling and is only trying not to drown in his thoughts and feelings. Introducing cardiac coherence into the world of oncology makes it possible to provide a method of preparing for the onset of anxiety. It is very complicated to anticipate anxiety and sometimes impossible to detect its triggers, but training your mind and spirit to react to the micro-signs that herald an emotional catastrophe is essential, all the more so in oncology medicine where the body is bruised.

What we have observed is linked to the person's basic level of stress. Is there a mental invasion, a cognitive disorder or even a difficulty in concentrating on myself that prevents access to the full potential of this method? As well as praising this technique, which has proved its worth, it sometimes gives an indication of a person's emotional and psychic interiority. It is by working in combination with psychotherapy that real, effective care can be provided in an oncology medicine that aims to be closer to humanity.

---

Biography

Nabhan Linda is a clinical psychologist specialising in oncology. She has worked with a large number of psychiatric patients in hospital, then oncology patients in adult wards, before developing her private practice. A cardiac coherence practitioner and founder of the OncopsyHeart Mindcare collective, she continues to develop her practice and her knowledge through numerous articles on oncology medicine.

---

📅 Event Dates: November 17–19, 2025
📍 Venue: Village Hotel Changi, 1 Netheravon Rd, Singapore 508502
🌐 Event Website: https://cancer.miconferences.com/
📧 Email: cancer@mathewsconference.com
📞 Phone: +1 (312) 462-4448
📱 WhatsApp: +1 (424) 377 0967

🔗 Follow us for updates:

• Facebook: Mathews Events
• X (Twitter): Cancer World Conference

# Cardiaccoherence #Oncology #anxiety #NervousSystem #psychotherapy #Cancer2025 #MedicalOncologyConferences #UpcomingOncologyConferences #CancerResearch